Please use this identifier to cite or link to this item:
|Title:||Interferon monotherapy in chronic hepatitis B||Authors:||Guan, R.||Issue Date:||2000||Citation:||Guan, R. (2000). Interferon monotherapy in chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia) 15 (SUPPL. MAY) : E34-E40. ScholarBank@NUS Repository. https://doi.org/10.1046/j.1440-1746.2000.02101.x||Abstract:||Interferon-alpha (IFN-α) has been the only approved agent for the treatment of chronic hepatitis B in most countries, but this is rapidly changing. It is expensive, associated with frequent and unpleasant side effects, has limited efficacy and is ineffective in subjects with no/mild liver necroinflammation. Loss of HBsAg and viral replication markers occur 6% and 20%, more often in IFN-treated subjects than controls. The most important factors that will predict favourable response to IFN-α therapy are elevated ALT and low serum HBV DNA levels. Chinese patients and children with active liver have similar response rates as Caucasian adults with equivalent ALT levels. Patients with HBeAg negative disease fare less well. Long-term follow up has shown that most IFN responders maintained their response although very few people have complete eradication of HBV.||Source Title:||Journal of Gastroenterology and Hepatology (Australia)||URI:||http://scholarbank.nus.edu.sg/handle/10635/132890||ISSN:||08159319||DOI:||10.1046/j.1440-1746.2000.02101.x|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 3, 2019
WEB OF SCIENCETM
checked on Nov 26, 2019
checked on Nov 29, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.